大剂量法乐通加EP方案治疗耐药晚期非小细胞肺癌临床分析

目的评价大剂量法乐通加EP方案治疗难治性晚期非小细胞肺癌的疗效和毒副反应.方法既往对含顺铂为主的化疗方案耐药的晚期非小细胞肺癌采用大剂量的法乐通加EP方案治疗,法乐通480 mg,口服,连用7.5 d;鬼臼乙叉甙100 mg/m2,静滴,第4～6天;顺铂80 mg/m2,静滴,第4天,每4周重复.结果共50例进入临床研究,可评价疗效43例,1例完全缓解,8例部分缓解,总有效率为20.9%(按ITT计算为18.0%);中位生存期和无疾病进展生存期分别为8.1和3.2个月;1年生存率为37.2%.主要的不良反应为轻至中度的骨髓抑制、恶心和呕吐.结论大剂量法乐通加EP方案治疗对铂类为主的化疗方案耐药的晚期非小细胞肺癌效果较好,不良反应轻,耐受性好.

High-dose toremifene plus EP regimen in the treatment of refractory advanced non-small cell lung cancer

Objective To evaluate the efficacy and safety of high-dose toremifene plus EP regimen in the treatment of refractory advanced non-small cell lung cancer (NSCLC).Methods The patients with previously DDP-resistant advanced NSCLC were treated with high-dose toremifene (480 mg,po,d1-7.5)plus EP regimen C (Vp-16 100 mg/m2 iv d4-6,DDP 80 mg/m2 iv d4) every 4 weeks.Results A total of 50 cases with advanced NSCLC resistant to DDP were enrolled,and 43 cases were valuable for efficacy assessment.One patient reached complete response (CR),8 reached partial response (PR),and the overall response rate was 20.9% (with ITT equal to 18.0%).The median survival time and the median progression-free survival time was 8.1 and 3.2 months respectively and 1-year survival rate was 37.2%.The major adverse effects were mild myelosuppression,nause and vomiting.Conclusions The high-dose toremifene plus EP regimen is effective in the treatment of advanced NSCLC resistant to DDP,and the adverse effects were tolerable.